Tags

Type your tag names separated by a space and hit enter

Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
HIV Med 2006; 7(2):99-104HM

Abstract

OBJECTIVE

Few data exist on the efficacy of antiretroviral therapy in individuals infected with HIV in the Caribbean. We evaluated the virological and immunological responses of HIV-infected adults starting highly active antiretroviral therapy (HAART).

DESIGN

This was a prospective observational cohort study.

METHODS

A total of 158 antiretroviral-naive patients who initiated HAART between January 2002 and March 2003, and completed at least 6 months of treatment and follow up, were included in the analysis. The response to therapy was assessed by changes in CD4 cell counts and viral loads from baseline. The mean increase in CD4 cell count, the rate of virological success (a viral load of <50 HIV-1 RNA copies/mL) and the rate of immunological success (an increase in CD4 cell count of > or =50 cells/microL over the baseline value) after commencing HAART were measured.

RESULTS

In total, 82% of patients (123 of 150) achieved viral loads of <50 copies/mL after 6 months of therapy. Viral success rate after 6 months of HAART was similar irrespective of gender, pre-HAART CD4 cell count and pre-HAART viral load. However, patients older than 40 years were significantly more likely to achieve virological success than those younger than 40 years. At 6 months after starting HAART, 79.5% of patients were estimated to have achieved immunological success and 17.9% had an increase in CD4 cell count of > or =200 cells/microL over the baseline value. The median increase in CD4 cell count for the 156 patients who had CD4 cell counts at baseline and at 6 months of therapy was 122 cells/microL.

CONCLUSION

In this cohort of antiretroviral-naive HIV-infected adults, there was a high rate of virological and immunological success after 6 months of HAART, irrespective of the pre-HAART viral load and CD4 cell count.

Authors+Show Affiliations

Ladymeade Reference Unit, University of the West Indies, Cave Hill Campus, Barbados.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16420254

Citation

Kilaru, K R., et al. "Immunological and Virological Responses to Highly Active Antiretroviral Therapy in a Non-clinical Trial Setting in a Developing Caribbean Country." HIV Medicine, vol. 7, no. 2, 2006, pp. 99-104.
Kilaru KR, Kumar A, Sippy N, et al. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. HIV Med. 2006;7(2):99-104.
Kilaru, K. R., Kumar, A., Sippy, N., Carter, A. O., & Roach, T. C. (2006). Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. HIV Medicine, 7(2), pp. 99-104.
Kilaru KR, et al. Immunological and Virological Responses to Highly Active Antiretroviral Therapy in a Non-clinical Trial Setting in a Developing Caribbean Country. HIV Med. 2006;7(2):99-104. PubMed PMID: 16420254.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. AU - Kilaru,K R, AU - Kumar,A, AU - Sippy,N, AU - Carter,A O, AU - Roach,T C, PY - 2006/1/20/pubmed PY - 2006/8/22/medline PY - 2006/1/20/entrez SP - 99 EP - 104 JF - HIV medicine JO - HIV Med. VL - 7 IS - 2 N2 - OBJECTIVE: Few data exist on the efficacy of antiretroviral therapy in individuals infected with HIV in the Caribbean. We evaluated the virological and immunological responses of HIV-infected adults starting highly active antiretroviral therapy (HAART). DESIGN: This was a prospective observational cohort study. METHODS: A total of 158 antiretroviral-naive patients who initiated HAART between January 2002 and March 2003, and completed at least 6 months of treatment and follow up, were included in the analysis. The response to therapy was assessed by changes in CD4 cell counts and viral loads from baseline. The mean increase in CD4 cell count, the rate of virological success (a viral load of <50 HIV-1 RNA copies/mL) and the rate of immunological success (an increase in CD4 cell count of > or =50 cells/microL over the baseline value) after commencing HAART were measured. RESULTS: In total, 82% of patients (123 of 150) achieved viral loads of <50 copies/mL after 6 months of therapy. Viral success rate after 6 months of HAART was similar irrespective of gender, pre-HAART CD4 cell count and pre-HAART viral load. However, patients older than 40 years were significantly more likely to achieve virological success than those younger than 40 years. At 6 months after starting HAART, 79.5% of patients were estimated to have achieved immunological success and 17.9% had an increase in CD4 cell count of > or =200 cells/microL over the baseline value. The median increase in CD4 cell count for the 156 patients who had CD4 cell counts at baseline and at 6 months of therapy was 122 cells/microL. CONCLUSION: In this cohort of antiretroviral-naive HIV-infected adults, there was a high rate of virological and immunological success after 6 months of HAART, irrespective of the pre-HAART viral load and CD4 cell count. SN - 1464-2662 UR - https://www.unboundmedicine.com/medline/citation/16420254/Immunological_and_virological_responses_to_highly_active_antiretroviral_therapy_in_a_non_clinical_trial_setting_in_a_developing_Caribbean_country_ L2 - https://doi.org/10.1111/j.1468-1293.2006.00347.x DB - PRIME DP - Unbound Medicine ER -